Adult Myopia Epidemiology Forecast
DelveInsight’s ‘Adult Myopia–Epidemiology Forecast—2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology Adult Myopia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2018–2030
Adult Myopia Disease Understanding
Myopia refers to a spectrum of ocular disorders in which the far point of the eye is closer to the retina than infinity. It is becoming a worldwide epidemic and imposes a tremendous public health burden. As a consequence, the global initiative for the elimination of avoidable blindness has grouped refractive error as one of five leading causes of blindness and visual impairment in the world.
Myopia can be categorized by severity and age of onset. Severity is often categorized as low myopia (between − 0.50 and − 2.99 D), moderate myopia (between − 3.00 and − 5.99 D), and high myopia as worse than or equal to − 6.00 D. The signs and symptoms for myopia include squinting, feeling fatigued when driving or playing sports along with headache and strain.
Age is one of the major risk factors for myopia and visual stress experienced by adults as a result of doing detailed work, such as reading or using a computer leads to development and progression of myopia over time.
Myopia could lead to permanent loss of sight and it has been associated with complications, such as myopic macular degeneration, retinal detachment, cataract, and open angle glaucoma. These complications can lead to irreversible visual impairment later in life.
Myopia and its associated complications are an increasing public health concern. While glasses and contact lens correction are valuable in treating the symptomatic vision changes associated with myopia, they do not change the anatomic progression of the myopic eye. Low-dose atropine use (0.01%) remains the most encouraging treatment choice available at this time, though more studies are needed to identify its optimal use. Additional environmental studies will also help determine if there are lifestyle changes that could slow myopia’s progression. In the meantime, vision screening and early detection remain essential for diagnosis and correction to avoid the loss of correctable, functional vision.
According to a study by Retina Today (2019), in 2010, an estimated 1.9 billion people (27% of the world’s population) were myopic, and 70 million of them (2.8%) had high myopia. These numbers are projected to rise to 52% and 10%, respectively, by 2050.
Adult Myopia Epidemiology
The Adult Myopia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Adult Myopia epidemiology segmented as the Total Prevalent Population of Adult Myopia and Prevalence of myopic choroidal neovascularization. The report includes the Prevalent scenario of Adult Myopia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country Wise- Adult Myopia Epidemiology
The epidemiology segment also provides the Adult Myopia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent population of Adult Myopia Associated in 7MM countries was estimated to be 213,211,282 cases in 2020 and is expected to increase at a CAGR of 2% for the study period (2018–2030).
- As per the estimates, United States has the highest Prevalent population of Adult Myopia
- Among the EU5 countries, Germany had the highest prevalent population of Adult Myopia. On the other hand, Spain had the lowest number of cases as 13,248,758 cases in 2020.
Scope of the Report
- Adult Myopia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
- Adult Myopia Epidemiology Report and Model provide an overview of the risk factors and global trends of Adult Myopia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight into the historical and forecasted patient pool of Adult Myopia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps recognize the growth opportunities in the 7MM concerning the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Adult Myopia
- The report provides the segmentation of the Adult Myopia epidemiology by Prevalent Cases of Adult Myopia in 7MM
- The report provides the segmentation of the Adult Myopia epidemiology by Prevalent Cases of Myopic CNV in 7MM
- 10-year Forecast of Adult Myopia epidemiology
- 7MM Coverage
- Total Prevalent Cases of Adult Myopia
- Prevalent Cases according to segmentation: Prevalent Cases of Myopic CNV
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM concerning the patient population about Adult Myopia?
- What are the key findings of Adult Myopia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2018–2030)?
- What would be the total number of patients with Adult Myopia across the 7MM during the forecast period (2018–2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018–2030)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2018–2030)?
- What are the disease risk, burden, and unmet needs of Adult Myopia?
- What are the currently available treatments for Adult Myopia?
Reasons to buy
The Adult Myopia Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Adult Myopia market
- Quantify patient populations in the global Adult Myopia market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adult Myopia therapeutics in each of the markets covered
- Understand the magnitude of Adult Myopia population by its Prevalence cases
- Understand the magnitude of Adult Myopia population by its Types-specific cases
- The Adult Myopia epidemiology report and model was written and developed by Masters and PhD level epidemiologists
- The Adult Myopia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population